Literature DB >> 12167597

CNP production in the kidney and effects of protein intake restriction in nephrotic syndrome.

Alessandro Cataliotti1, Mauro Giordano, Emanuela De Pascale, Gelsomina Giordano, Pietro Castellino, Michihisa Jougasaki, Lisa C Costello, Guido Boerrigter, Toshihiro Tsuruda, Paola Belluardo, Shang-Chiun Lee, Brenda Huntley, Sharon Sandberg, Lorenzo S Malatino, John C Burnett.   

Abstract

C-type natriuretic peptide (CNP) possesses well-established cardiovascular properties. Although present in the mammalian kidney, CNP production in human kidney and its modulation in human renal disease remain less defined. We investigated the presence of CNP in normal human kidney and in patients with nephrotic syndrome (NS). We also addressed whether or not a low-protein diet (LPD) alters plasma CNP and urinary CNP excretion in NS. In situ hybridization studies demonstrated CNP mRNA expression in tubular cells and glomeruli of normal human kidneys. CNP immunoreactivity was positive in proximal, distal, and medullary collecting duct tubular cells in both controls and patients with NS. The ratios of plasma CNP and urinary CNP to creatinine were significantly higher in patients with NS compared with controls. Urinary CNP, but not plasma CNP, was significantly lowered in patients with NS after an LPD. Similarly, the ratios of urinary protein to creatinine and urinary albumin to creatinine, but not urinary guanosine 3',5'-cyclic monophosphate to creatinine, decreased significantly with an LPD. These data confirm and extend previous reports and demonstrate for the first time the presence of CNP in human kidney with NS. We also report increased plasma CNP concentration and urinary CNP excretion in NS patients and a significant reduction of CNP excretion with an LPD. Our findings demonstrate that CNP metabolism is altered in patients with NS and support the hypothesis that activation of renal CNP can be partially offset by an LPD. These results underscore that the beneficial effect of an LPD on protein excretion is paralleled by a substantial reduction in intrarenal CNP release.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12167597     DOI: 10.1152/ajprenal.00372.2001

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  12 in total

1.  Urinary C-type natriuretic peptide excretion: a potential novel biomarker for renal fibrosis during aging.

Authors:  S Jeson Sangaralingham; Denise M Heublein; Joseph P Grande; Alessandro Cataliotti; Andrew D Rule; Paul M McKie; Fernando L Martin; John C Burnett
Journal:  Am J Physiol Renal Physiol       Date:  2011-08-24

Review 2.  Anti-neutral endopeptidase, natriuretic peptides disarrangement, and proteinuria onset in membranous nephropathy.

Authors:  Peng Hu; Qiang Xuan; Bo Hu; Ling Lu; Yuan Han Qin
Journal:  Mol Biol Rep       Date:  2012-12-28       Impact factor: 2.316

Review 3.  Urinary C-type natriuretic peptide: an emerging biomarker for heart failure and renal remodeling.

Authors:  Rosita Zakeri; John C Burnett; S Jeson Sangaralingham
Journal:  Clin Chim Acta       Date:  2014-12-12       Impact factor: 3.786

Review 4.  Hormonal Regulation of Renal Fibrosis.

Authors:  Polina A Abramicheva; Egor Y Plotnikov
Journal:  Life (Basel)       Date:  2022-05-16

5.  Overexpressed C-type natriuretic peptide serves as an early compensatory response to counteract extracellular matrix remodeling in unilateral ureteral obstruction rats.

Authors:  Peng Hu; Jing Wang; Xue Qi Zhao; Bo Hu; Ling Lu; Yuan Han Qin
Journal:  Mol Biol Rep       Date:  2012-10-17       Impact factor: 2.316

6.  Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP.

Authors:  Ondrej Lisy; Brenda K Huntley; Daniel J McCormick; Paul A Kurlansky; John C Burnett
Journal:  J Am Coll Cardiol       Date:  2008-07-01       Impact factor: 24.094

Review 7.  Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics.

Authors:  Sarah Mangiafico; Lisa C Costello-Boerrigter; Ingrid A Andersen; Alessandro Cataliotti; John C Burnett
Journal:  Eur Heart J       Date:  2012-08-31       Impact factor: 29.983

8.  Urinary C-type natriuretic peptide: a new heart failure biomarker.

Authors:  Rosita Zakeri; S Jeson Sangaralingham; Sharon M Sandberg; Denise M Heublein; Christopher G Scott; John C Burnett
Journal:  JACC Heart Fail       Date:  2013-04       Impact factor: 12.035

9.  Prognostic Value of Urinary and Plasma C-Type Natriuretic Peptide in Acute Decompensated Heart Failure.

Authors:  Xiao Ma; Yang Chen; Shawn H Reginauld; Christopher G Scott; Seethalakshmi R Iyer; Jacob J Schaefer; Tomoko Ichiki; Horng H Chen; Andrew D Rule; John C Burnett; S Jeson Sangaralingham
Journal:  JACC Heart Fail       Date:  2021-07-07       Impact factor: 12.544

10.  Long-Term Structural and Functional Myocardial Adaptations in Healthy Living Kidney Donors: A Pilot Study.

Authors:  Diego Bellavia; Alessandro Cataliotti; Francesco Clemenza; Cesar Hernandez Baravoglia; Angelo Luca; Marcello Traina; Bruno Gridelli; Tullio Bertani; John C Burnett; Cesare Scardulla
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.